← Leaderboards
Panagiotis Z Anastasiadis
Mayo Clinic Jacksonville
$6,890,926
Attributed
$6,890,926
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $738.6K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,890,926 · 7
By mechanism
R01$4,359,858 · 3
P50$1,438,344 · 1
R21$416,925 · 1
R56$342,822 · 1
P30$332,977 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorInsightMigrationCellsSignal TransductionAngiogenesisCell AdhesionNeoplastic CellMemberCancer CellMediatingGliomaIn VitroPathway InteractionsFamilyBaseGrowthMolecularGeneticCell DivisionMalignant NeoplasmsBasic ScienceTumor ProgressionIn Vivo
Grant awards (26)
Cell Biology Program$70,471
P30 · FY2023 · CA · contact PI
Role of the Syx-RhoA signaling axis in glioma cell growth and dissemination$342,835
R01 · FY2022 · NS · contact PI
Cell Biology Program$70,595
P30 · FY2022 · CA · contact PI
Cell Biology Program$70,471
P30 · FY2021 · CA · contact PI
Role of the Syx-RhoA signaling axis in glioma cell growth and dissemination$342,835
R01 · FY2020 · NS · contact PI
Cell Biology Program$72,913
P30 · FY2020 · CA · contact PI
Role of the Syx-RhoA signaling axis in glioma cell growth and dissemination$342,835
R01 · FY2019 · NS · contact PI
Cell Biology Program$48,527
P30 · FY2019 · CA · contact PI
Role of the Syx-RhoA signaling axis in glioma cell growth and dissemination$342,835
R01 · FY2018 · NS · contact PI
Role of the Syx-RhoA signaling axis in glioma cell growth and dissemination$342,822
R56 · FY2017 · NS · contact PI
Clinical Relevance of Chromosome 5p/9p/20q/8q Germline Alterations in Glioma$342,209
P50 · FY2015 · CA · contact PI
Clinical Relevance of Chromosome 5p/9p/20q/8q Germline Alterations in Glioma$369,782
P50 · FY2014 · CA · contact PI
Combining Anti-Invasive and Anti-Angiogenic Therapies for the treatment of GBM$323,884
R01 · FY2014 · NS · contact PI
Combining Anti-Invasive and Anti-Angiogenic Therapies for the treatment of GBM$315,723
R01 · FY2013 · NS · contact PI
Combining Anti-invasive and Anti-angiogenic Therapies for the Treatment of$315,362
P50 · FY2013 · CA · contact PI
Combining Anti-invasive and Anti-angiogenic Therapies for the Treatment of$410,991
P50 · FY2012 · CA · contact PI
Combining Anti-Invasive and Anti-Angiogenic Therapies for the treatment of GBM$327,646
R01 · FY2012 · NS · contact PI
Combining Anti-Invasive and Anti-Angiogenic Therapies for the treatment of GBM$327,207
R01 · FY2011 · NS · contact PI
Role of the polarity RhoGEF PLEKHG5 on brain tumor dispersal$187,425
R21 · FY2011 · NS · contact PI
Combining Anti-Invasive and Anti-Angiogenic Therapies for the treatment of GBM$345,494
R01 · FY2010 · NS · contact PI
Role of the polarity RhoGEF PLEKHG5 on brain tumor dispersal$229,500
R21 · FY2010 · NS · contact PI
Cadherin-p120 signaling in motility and invasiveness$262,409
R01 · FY2008 · CA · contact PI
Cadherin-p120 signaling in motility and invasiveness$262,409
R01 · FY2007 · CA · contact PI
Cadherin-p120 signaling in motility and invasiveness$270,246
R01 · FY2006 · CA · contact PI
Cadherin-p120 signaling in motility and invasiveness$276,750
R01 · FY2005 · CA
Cadherin-p120 signaling in motility and invasiveness$276,750
R01 · FY2004 · CA